𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Histone deacetylase inhibitors and periodontal bone loss

✍ Scribed by M. D. Cantley; P. M. Bartold; V. Marino; D. P. Fairlie; G. T. Le; A. J. Lucke; D. R. Haynes

Book ID
111262334
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
509 KB
Volume
46
Category
Article
ISSN
0022-3484

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Histone Deacetylase Inhibitors
Histone Deacetylase Inhibitors
✍ Thomas A. Miller; David J. Witter; Sandro Belvedere πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons βš– 53 KB
Prospects: Histone deacetylase inhibitor
Prospects: Histone deacetylase inhibitors
✍ Milos Dokmanovic; Paul A. Marks πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 160 KB

## Abstract Histone deacetylase (HDAC), inhibitors represent a new class of targeted anti‐cancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients. The HDAC inh

Dietary agents as histone deacetylase in
Dietary agents as histone deacetylase inhibitors
✍ Melinda C. Myzak; Emily Ho; Roderick H. Dashwood πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 109 KB

## Abstract In cancer cells, an imbalance often exists between histone acetyltransferase (HAT) and histone deacetylase (HDAC) activities, and various drug companies are actively seeking competitive HDAC inhibitors for chemotherapeutic intervention. Cancer cells appear to be more sensitive than nont